BiotechTube

LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SC

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperlipidemia

Conditions

Hyperlipidemia

Trial Timeline

Sep 1, 2011 → Jun 1, 2013

NCT ID
NCT01426412

About LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SC

LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SC is a phase 1 stage product being developed by Eli Lilly for Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01426412. Target conditions include Hyperlipidemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01426412Phase 1Completed

Competing Products

20 competing products in Hyperlipidemia

See all competitors
ProductCompanyStageHype Score
VK2809 + PlaceboViking TherapeuticsPhase 2
47
YHP1701 + YHR1703 + YHR1704YuhanPhase 3
77
YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placeboYuhanPhase 3
77
Diet+pravastatinDaiichi SankyoApproved
85
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
85
Minute Maid Heart Wise orange juice + WelcholDaiichi SankyoApproved
85
Pravafen + Pravastatin + FenofibrateShionogiPhase 3
77
Evacetrapib + Atorvastatin + Ezetimibe + PlaceboEli LillyPhase 3
77
exenatideEli LillyPre-clinical
23
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injectionsJiangsu Hengrui MedicinePhase 1
33
SHR-1209Jiangsu Hengrui MedicinePhase 1
33
SHR-1209 + PlaceboJiangsu Hengrui MedicinePhase 1/2
41
Rosuvastatin + AtorvastatinAstraZenecaPhase 2
52
Rosuvastatin (Crestor)AstraZenecaApproved
85
simvastatin + EzetimibeMerckApproved
85
MK-0524A + Atorvastatin + SimvastatinMerckPhase 3
77
simvastatin 20 mg/ezetimibeMerckPhase 2/3
65
Enlicitide + Rosuvastatin + Placebo for Enlicitide + Placebo for RosuvastatinMerckPhase 3
77
Sitagliptin + PlaceboMerckPhase 2/3
65
100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) + Placebo + 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)NovartisPhase 1
33

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85